新华医疗 拟控股中帜生物

Core Viewpoint - Xinhua Medical plans to acquire a 36.19% stake in Wuhan Zhongzhi Biotechnology Co., Ltd. for 166 million yuan, aiming to enhance its in vitro diagnostic product line and overall competitiveness [1][4][10] Group 1: Acquisition Details - The acquisition involves purchasing shares from 10 parties, including individuals and investment funds, totaling 14.1247 million shares at a price of 11.7864 yuan per share [2][3] - The total consideration for the acquisition is 166 million yuan, funded by the company's own resources [3][6] Group 2: Strategic Implications - The acquisition will allow Xinhua Medical to enrich its product offerings in the field of pathogen microorganism testing and improve its R&D capabilities [4][5] - Zhongzhi Biotechnology will become a subsidiary, enhancing capital operation channels and creating new business growth points through resource integration [5][9] Group 3: Company Background - Zhongzhi Biotechnology, established in March 2011, focuses on the R&D, production, and sales of in vitro diagnostic reagents, with a registered capital of 39.0279 million yuan [7][8] - The company reported revenues of 120 million yuan in 2023 and 49.1452 million yuan from January to May 2024, with net profits of 15.6353 million yuan and a loss of 80,600 yuan during the same periods [7]